Fleroxacin pharmacokinetics in patients with liver cirrhosis.
In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated. Fleroxacin (400 mg) was administered orally and intravenously to each subject in a random c...
שמור ב:
| הוצא לאור ב: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Microbiology (ASM)
1992
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC190569/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1622175/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.36.3.632 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|